You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
Hemex Health is developing a diagnostic test that it said could particularly benefit rural and economically challenged areas of the world.
Johns Hopkins researchers have developed a proof-of-concept test for research use that they hope to eventually refine for clinical use at the point of care.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
University of Washington scientists found that by adding a material first isolated from shellfish, they could increase the sensitivity of standard bioassays by up to 1,000 times.
A diagnostic test could be available within about a year that researchers and clinicians could use to diagnose patients and develop therapies.
Researchers from the University of Illinois said their test may one day enable patients to identify sepsis at home and transmit test results immediately to a physician.
The researchers are developing a clinical assay that would use multiple biomarkers to analyze low-abundance peptides indicative of preterm risk.
The test measures quantities of white blood cells and CD64 on the surface of neutrophils, enabling the immune system's response to sepsis to be monitored.
Researchers are working with the Australian Ministry of Health to commercialize a diagnostic test that employs the biomarker and could be available within two to five years.